TABLE 2.
Samples Grouped by Site of Analysis
| Serostatus following dose 2 (positive:negative, % seroconverted) | Difference between centers (p) | ||
|---|---|---|---|
| Cardiff | QMUL | ||
| No DMT | 84:5 (94%) | 2:1 (66%) | NS |
| Anti‐CD20 mAb a | 25:59 (30%) | 8:42 (16%) | NS |
| Natalizumab | 48:2 (96%) | 8:3 (73%) | 0.04 |
| Alemtuzumab | 22:1 (96%) | 3:2 (60%) | NS |
| Dimethyl fumarate | 27:2 (93%) | 8:1 (89%) | NS |
| Cladribine | 8:1 (89%) | 8:3 (73%) | NS |
| Glatiramer acetate | 3:0 (100%) | NA | ‐ |
| Fingolimod | 12:21 (36%) | 0:3 (0%) | NS |
| Interferon beta | 5:1 (83%) | NA | ‐ |
| Teriflunomide | 3:0 (100%) | NA | ‐ |
a
Ocrelizumab, rituximab, and ofatumumab.
DMT = disease modifying therapy; mAb = monoclonal antibody; NA = not applicable; NS = not significant; QMUL = Queen Mary University of London.